Pharmaceutical compositions for treating rheumatic joint disease, preparation method thereof and use thereof

Abstract

The invention provides pharmaceutical compositions for treating rheumatic joint disease, a preparation method thereof and application thereof. The pharmaceutical compositions mainly consist of the following raw materials in parts by weight: 10-70 parts of silky ant, 10-50 parts of astragalus mongholicus, 5-40 parts of pawpaw, 5-40 parts of salted aconite root and 2-20 parts of pseudo-ginseng. The invention further provides a preparation method of the pharmaceutical compositions and the use of the pharmaceutical compositions. The experiment improves that the pharmaceutical compositions provided by the invention have the effects of deficiency tonifying, consolidating basis, eliminating evil and smoothening numbness, not only can be used for effectively treating and relieving the arthralgia, the morning stiffness, the numbness and the bad flexibility caused by the rheumatism and the rheumatoid arthritis, but also can be used for preventing, treating and relieving the kidney function harm caused by the rheumatism, have the functions for treating the pathological changes such as arthrocele, pain, inhibited bending and stretching and the like, and can be particularly used for the rheumatic arthritis, the chronic infectious arthritis, the joint synovitis and the rheumatoid renal damage.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition composed of black ants, salt aconite, astragalus, papaya and notoginseng, belonging to the technical field of traditional Chinese medicine. Background technique [0002] Rheumatoid arthritis (Rheumatoid Arthritis, RA) belongs to the category of "arthritis syndrome" in Chinese medicine, with a high incidence rate, most of which are young adults aged 25 to 55, and the incidence rate of women is higher than that of men, with a male to female ratio of 1:4. There are hundreds of millions of patients worldwide. According to statistics, the prevalence rate of RA in foreign countries is 1-2%, and it is as high as 5% in some regions; the incidence rate in my country is about 0.74%, and there are about 15 million patients; 50% of rheumatoid arthritis patients become disabled in two years, and 70% in three years. The average life expectancy of patients with rheum...

AI Technical Summary

Problems solved by technology

The International League Against Rheumatism divides the existing anti-rheumatic drugs into two categories, namely anti-rheumatic drugs for improving symptoms and anti-rheumatic drugs for disease control. Rheumatism drugs are often used in combination in clinical practice in order to achieve the purpose of disease control, but in terms of the short-term and long-term curative effects obtained so far, the results are not satisfactory; although biological therapy has been carried out in recent years, it is expensive and oral The shortcomings of poor activity and inability to selectively act on target tissues limit its application; gene therapy seems to be able to overcome some of the defects of biological therapy in theory, but in more than 300 clinical studies in the world, more than 3,000 patients who have received gene therapy , none clearly demonstrated clinical improvement

Existing clinical drugs such as salicylic acid and other non-steroidal anti-inflammatory drugs, antimalarials, penicillamine, tripterygium preparations, gold preparations, and even corticosteroids have unsatisfactory therapeutic effects and large side effects

Images